Medical Devices Late Stage Investors & VC Firms
489 firms in this list, with a median first check of $1.1M. 105 of them lead rounds. Generated from verified public data and updated continuously.
Champel Capital
JerusalemSeed–Late Stage
6 people
Mohr Davidow Ventures
San MateoSeed–Late Stage$200K – $4M
6 people
Montreux Equity Partners
San FranciscoGrowth–Late Stage$10M – $20M
3 people
OTV
New YorkSeries C–Late Stage
Cathay Health
San FranciscoSeed–Late Stage
5 people
Mizuho Capital
TokyoPre-Seed–Late Stage$1.5M – $340M
1 person
Ridgeback Capital
MiamiSeed–Late Stage
1 person
dsm-firmenich Venturing
MaastrichtPre-Seed–Late Stage$108K – $5.4M
9 people
SBI Investment Korea Co. Ltd.
SeoulSeed–Late Stage$2.5M – $33M
INP Capital
VancouverSeed–Late Stage
6 people
Black Marble Capital Management
TaipeiSeed–Late Stage
12 people
Triangle Venture Capital Group
Bensheim-AuerbachPre-Seed–Late Stage$1.6M – $3.2M
3 people
V Ventures
SingaporePre-Seed–Late Stage
6 people
Whistler Capital Partners
NashvilleSeries C–Late Stage
X2 Equity GmbH
MünchenSeed–Late Stage
3 people
NGN Capital
New YorkSeries A–Late Stage
5 people
Sanara Capital
Ra'ananaSeed–Late Stage
1 person
Stone Bridge Ventures
SeoulSeed–Late Stage$1.4M – $19M
LifeSci Venture Partners
New YorkSeries A–Late Stage
2 people
Ferd
OsloGrowth–Late Stage$43.2M – $270M
1 person
MaRS
TorontoPre-Seed–Late Stage
1 person
Xerys
ParisSeed–Late Stage$16M – $97M
Soleus Capital
GreenwichLate Stage
2 people
Level Eight Ventures
Ann ArborSeed–Late Stage
4 people
Related lists
Late Stage Investors & VC Firms (2974)Late Stage Investors & VC Firms in North America (1695)Late Stage Investors & VC Firms in United States (1516)Medical Devices Investors & VC Firms (1452)Medical Devices Seed Investors & VC Firms (1202)Medical Devices Series A Investors & VC Firms (1187)Late Stage Investors & VC Firms in Europe (965)Medical Devices Investors & VC Firms in North America (948)Healthtech Late Stage Investors & VC Firms (925)Late Stage Investors & VC Firms in Global (904)
Data sourced from public filings and firms' own websites — see our methodology.


































